{"hands_on_practices": [{"introduction": "Understanding the public health impact of a genetic disorder begins with population genetics. While the incidence of an autosomal recessive condition like alkaptonuria may be known, the Hardy-Weinberg principle provides a powerful tool to estimate the frequency of heterozygous carriers who do not show symptoms. This exercise will guide you through applying this fundamental model to translate disease incidence into carrier frequency, a crucial metric for genetic counseling and public health planning. [@problem_id:5010635]", "problem": "Alkaptonuria is an autosomal recessive disorder of tyrosine catabolism caused by deficiency of the enzyme Homogentisate 1,2-dioxygenase (HGD). In a large, randomly mating population with full penetrance and negligible selection and migration, the Hardy–Weinberg Equilibrium (HWE) model applies. Epidemiologic surveillance in a specific region finds that the incidence of alkaptonuria is one in $250{,}000$ live births. Treat the disease incidence as the squared frequency of the disease allele, so that the mutant allele frequency is $q$ with incidence $q^{2} = 1/250{,}000$. Using the small-$q$ approximation that the carrier (heterozygote) frequency is $2q$, compute:\n1) The carrier frequency $2q$ as a decimal.\n2) The expected number of carriers in a population of $1{,}000{,}000$ individuals.\n\nRound both results to four significant figures. Express the expected number of carriers as a pure count without units. Do not use a percentage sign; express all proportions as decimals or fractions.", "solution": "The problem statement is critically evaluated and found to be valid. It is scientifically grounded in the principles of population genetics, specifically the Hardy-Weinberg Equilibrium (HWE) model. The description of alkaptonuria as an autosomal recessive disorder is factually correct. The problem is well-posed, providing all necessary data (incidence rate, population size) and explicit instructions (use of the small-$q$ approximation, required precision for the answers) to arrive at a unique, meaningful solution. The language is objective and unambiguous.\n\nThe problem states that alkaptonuria is an autosomal recessive disorder and its incidence in the population corresponds to the frequency of the homozygous recessive genotype. In the context of the HWE model, this frequency is denoted by $q^2$, where $q$ is the frequency of the recessive (disease-causing) allele.\n\nThe given incidence is one in $250,000$ live births. Therefore, the frequency of the homozygous recessive genotype is:\n$$q^2 = \\frac{1}{250000}$$\nSolving for the frequency of the recessive allele, $q$:\n$$q = \\sqrt{\\frac{1}{250000}} = \\frac{1}{\\sqrt{250000}} = \\frac{1}{500}$$\nAs a decimal, the allele frequency is:\n$$q = 0.002$$\n\nThe problem requires the computation of two quantities.\n\n1) The carrier frequency, using the small-$q$ approximation.\nThe problem explicitly states to use the approximation that the carrier (heterozygote) frequency is $2q$. The exact frequency of carriers (heterozygotes) under HWE would be $2pq$, where $p=1-q$. For small values of $q$, $p \\approx 1$, and thus $2pq \\approx 2q$. Adhering to the problem's directive:\n$$\\text{Carrier frequency} \\approx 2q = 2 \\times 0.002 = 0.004$$\nThe problem requires this result to be rounded to four significant figures. To express $0.004$ with four significant figures, we write it as:\n$$0.004000$$\n\n2) The expected number of carriers in a population of $1,000,000$ individuals.\nThe expected number of carriers is the product of the carrier frequency and the total population size, $N$.\n$$N = 1,000,000$$\nUsing the calculated carrier frequency:\n$$\\text{Expected number of carriers} = (2q) \\times N = 0.004 \\times 1,000,000$$\n$$\\text{Expected number of carriers} = 4000$$\nThe problem requires this result to be rounded to four significant figures. The calculated value is an exact integer, $4000$. The requirement for four significant figures on an exact integer result implies that the trailing zeros are significant. Thus, the result is presented as $4000$.\n\nThe two requested values are the carrier frequency, $0.004000$, and the expected number of carriers, $4000$.", "answer": "$$\\boxed{\\begin{pmatrix} 0.004000 & 4000 \\end{pmatrix}}$$", "id": "5010635"}, {"introduction": "Moving from population screening to individual diagnosis, quantitative analysis is key. For metabolic disorders like alkaptonuria, measuring the buildup of a specific metabolite, like homogentisic acid (HGA), is a cornerstone of diagnosis. This practice demonstrates a critical step in clinical chemistry: normalizing urinary analyte excretion to creatinine to account for variations in urine concentration, ensuring a reliable and comparable diagnostic metric. [@problem_id:5010663]", "problem": "A patient with clinically confirmed alkaptonuria due to deficiency of homogentisate $1,2$-dioxygenase (HGD) has a $24$ hour urine collection analyzed for homogentisic acid (HGA). In medical genetics and biochemical diagnostics, normalization of urinary biomarkers to creatinine is used to control for variable urine concentration, based on the core definition that normalized excretion expresses the mass of analyte per unit mass of creatinine. The laboratory reports a total $24$ hour urinary HGA of $4$ $\\text{g}$ and a total $24$ hour urinary creatinine of $1.5$ $\\text{g}$. Using fundamental unit conversion and ratio reasoning, compute the normalized urinary HGA excretion in $\\text{mg/g creatinine}$. Round your answer to three significant figures and express it in $\\text{mg/g creatinine}$.", "solution": "The problem requires the calculation of the normalized urinary homogentisic acid (HGA) excretion, a standard diagnostic metric in medical biochemistry. The validation process confirms that the problem is scientifically sound, well-posed, and contains all necessary information for a rigorous solution.\n\nThe fundamental definition of normalized excretion, as stated in the problem, is the ratio of the mass of the analyte to the mass of creatinine over a common collection period, which in this case is $24$ hours. Let $M_{HGA}$ represent the mass of HGA and $M_{creat}$ represent the mass of creatinine.\n\nThe given data are:\n$$M_{HGA} = 4 \\text{ g}$$\n$$M_{creat} = 1.5 \\text{ g}$$\n\nThe normalized excretion, which we denote as $E_{norm}$, is therefore calculated as:\n$$E_{norm} = \\frac{M_{HGA}}{M_{creat}}$$\n\nThe problem specifies that the final answer must be in units of milligrams per gram of creatinine ($\\text{mg/g creatinine}$). The provided mass of HGA is in grams ($\\text{g}$), so a unit conversion is required. The relationship between grams and milligrams is:\n$$1 \\text{ g} = 1000 \\text{ mg}$$\n\nWe convert the mass of HGA from grams to milligrams:\n$$M_{HGA} = 4 \\text{ g} \\times \\left(\\frac{1000 \\text{ mg}}{1 \\text{ g}}\\right) = 4000 \\text{ mg}$$\n\nNow we can compute the normalized excretion with the correct units. We substitute the value of $M_{HGA}$ in milligrams and the value of $M_{creat}$ in grams into the ratio:\n$$E_{norm} = \\frac{4000 \\text{ mg}}{1.5 \\text{ g}}$$\n\nTo perform the division, we can express the denominator $1.5$ as the fraction $\\frac{3}{2}$:\n$$E_{norm} = \\frac{4000}{\\frac{3}{2}} \\frac{\\text{mg}}{\\text{g}} = 4000 \\times \\frac{2}{3} \\frac{\\text{mg}}{\\text{g}} = \\frac{8000}{3} \\frac{\\text{mg}}{\\text{g}}$$\n\nThe numerical result of this division is a repeating decimal:\n$$E_{norm} = 2666.666... \\frac{\\text{mg}}{\\text{g}}$$\n\nThe final instruction is to round the answer to three significant figures. The number is $2666.\\overline{6}$. The first three significant figures are $2$, $6$, and $6$. The fourth significant figure is $6$. Since this digit is $5$ or greater, we round up the third significant figure ($6$) to $7$. The resulting sequence of significant digits is $267$. To preserve the magnitude of the number, a zero must be used as a placeholder in the units place.\n\nThus, the value rounded to three significant figures is $2670$.\n\nThe final calculated value for the normalized urinary HGA excretion is $2670 \\text{ mg/g creatinine}$.", "answer": "$$\\boxed{2670}$$", "id": "5010663"}, {"introduction": "The ultimate goal in medical genetics is often to devise effective treatments, and understanding their biochemical impact is paramount. For alkaptonuria, substrate reduction therapy with the drug nitisinone offers a modern approach by inhibiting an upstream enzyme in the tyrosine catabolic pathway. This advanced exercise challenges you to build a quantitative model, integrating Michaelis-Menten kinetics and steady-state metabolic principles, to predict how this therapeutic intervention will alter key metabolite levels in a patient. [@problem_id:5010601]", "problem": "An adult with alkaptonuria has a complete deficiency of homogentisate $1,2$-dioxygenase (HGD), so homogentisic acid (HGA) is not further metabolized after it is formed. In the tyrosine catabolic pathway, tyrosine is reversibly transaminated to $4$-hydroxyphenylpyruvate (abbreviated here as $4$-HPP) and then irreversibly converted to HGA by $4$-hydroxyphenylpyruvate dioxygenase (HPD). Assume the following, using well-tested biochemical principles as the fundamental base:\n\n- The conversion of $4$-HPP to HGA by HPD follows Michaelis–Menten kinetics with competitive inhibition by nitisinone. Let the Michaelis constant be $K_{m}$ (for $4$-HPP), the maximal rate be $V_{\\max}$, and the inhibitor dissociation constant be $K_{i}$.\n\n- The reversible transamination between tyrosine and $4$-HPP is fast relative to HPD, such that at steady state $[4\\text{-HPP}] = \\alpha\\,[\\text{Tyr}]$, where $[\\text{Tyr}]$ is the plasma tyrosine concentration and $\\alpha$ is a constant reflecting a near-equilibrium proportionality.\n\n- Whole-body tyrosine balance at steady state is determined by a constant input rate $R_{\\text{in}}$ (diet and proteolysis) and two output processes: HPD flux and other first-order clearance with rate constant $k_{\\text{other}}$. Thus, before and after inhibition at steady state, $R_{\\text{in}} = k_{\\text{other}}\\,[\\text{Tyr}] + v_{\\text{HPD}}$, where $v_{\\text{HPD}}$ is the HPD flux.\n\nYou are given the following experimentally supported and internally consistent parameter values for this patient before nitisinone:\n\n- Baseline plasma tyrosine concentration $[\\text{Tyr}]_{0} = 60$ µM.\n- Proportionality $\\alpha = 0.2$.\n- HPD $K_{m} = 50$ µM.\n- Baseline daily HGA production (equal to HPD flux at steady state) $v_{0} = 7.0$ mmol/day.\n- First-order tyrosine clearance constant $k_{\\text{other}} = 0.01$ mmol day$^{-1}$ µM$^{-1}$.\n\nThe patient is started on nitisinone, which competitively inhibits HPD with a stable plasma concentration $[\\text{I}] = 1.0$ µM and $K_{i} = 0.005$ µM.\n\nAssume that $R_{\\text{in}}$ remains constant with treatment, that the above relationships hold at the new steady state, and that HPD is the sole source of HGA. Using these assumptions and data, calculate the post-treatment values for:\n\n- Daily HGA production rate, and\n- Plasma tyrosine concentration.\n\nExpress your final answer as a row matrix with the first entry equal to the HGA production rate in mmol/day and the second entry equal to the plasma tyrosine concentration in µM. Round each entry to four significant figures.", "solution": "The problem is evaluated to be scientifically grounded, well-posed, objective, and internally consistent. It is based on established principles of enzyme kinetics and metabolic steady-state analysis. All data are provided, and the problem is structured to yield a unique, meaningful solution. Therefore, we proceed with the solution.\n\nThe problem requires us to calculate the new steady-state values for the HGA production rate and plasma tyrosine concentration after the administration of nitisinone, a competitive inhibitor of the enzyme $4$-hydroxyphenylpyruvate dioxygenase (HPD).\n\nThe solution strategy involves two main steps. First, we use the provided baseline (pre-treatment) steady-state data to determine the unknown system parameters, namely the maximal rate of the HPD enzyme ($V_{\\max}$) and the total input rate of tyrosine ($R_{\\text{in}}$). Second, we use these calculated parameters, along with the principles of competitive inhibition, to establish a new system of equations for the post-treatment steady state and solve for the desired quantities.\n\n**Step 1: Characterize the baseline (pre-treatment) steady state**\n\nWe are given the following baseline values:\n-   Plasma tyrosine concentration, $[\\text{Tyr}]_{0} = 60$ µM.\n-   Proportionality constant, $\\alpha = 0.2$.\n-   Michaelis constant for HPD, $K_{m} = 50$ µM.\n-   Baseline HPD flux (HGA production), $v_{0} = 7.0$ mmol/day.\n-   First-order tyrosine clearance constant, $k_{\\text{other}} = 0.01$ mmol day$^{-1}$ µM$^{-1}$.\n\nThe concentration of the HPD substrate, $4$-hydroxyphenylpyruvate ($4$-HPP), is related to the tyrosine concentration by $[4\\text{-HPP}] = \\alpha\\,[\\text{Tyr}]$.\nAt baseline, the substrate concentration is:\n$$[4\\text{-HPP}]_{0} = \\alpha\\,[\\text{Tyr}]_{0} = 0.2 \\times 60 \\text{ µM} = 12 \\text{ µM}$$\n\nThe flux through HPD, $v_{\\text{HPD}}$, follows Michaelis-Menten kinetics:\n$$v_{\\text{HPD}} = \\frac{V_{\\max}\\,[4\\text{-HPP}]}{K_m + [4\\text{-HPP}]}$$\nAt baseline, this flux is $v_{0}$. We can use this to solve for $V_{\\max}$:\n$$v_{0} = \\frac{V_{\\max}\\,[4\\text{-HPP}]_{0}}{K_m + [4\\text{-HPP}]_{0}}$$\n$$7.0 = \\frac{V_{\\max}\\,(12)}{50 + 12} = \\frac{12\\,V_{\\max}}{62}$$\n$$V_{\\max} = \\frac{7.0 \\times 62}{12} = \\frac{434}{12} = \\frac{217}{6} \\text{ mmol/day}$$\nWe will retain this exact fraction to maintain precision in subsequent calculations.\n\nNext, we determine the constant tyrosine input rate, $R_{\\text{in}}$, using the steady-state whole-body tyrosine balance equation:\n$$R_{\\text{in}} = k_{\\text{other}}\\,[\\text{Tyr}] + v_{\\text{HPD}}$$\nAt baseline:\n$$R_{\\text{in}} = k_{\\text{other}}\\,[\\text{Tyr}]_{0} + v_{0}$$\n$$R_{\\text{in}} = (0.01 \\text{ mmol day}^{-1} \\text{ µM}^{-1}) \\times (60 \\text{ µM}) + 7.0 \\text{ mmol/day}$$\n$$R_{\\text{in}} = 0.6 \\text{ mmol/day} + 7.0 \\text{ mmol/day} = 7.6 \\text{ mmol/day}$$\n\n**Step 2: Characterize the post-treatment steady state**\n\nWith nitisinone treatment, HPD is competitively inhibited. The inhibitor concentration is $[\\text{I}] = 1.0$ µM, and its dissociation constant is $K_{i} = 0.005$ µM. For competitive inhibition, the Michaelis-Menten equation is modified by an apparent Michaelis constant, $K_{m,\\text{app}}$:\n$$K_{m,\\text{app}} = K_m \\left(1 + \\frac{[\\text{I}]}{K_i}\\right)$$\n$$K_{m,\\text{app}} = 50 \\text{ µM} \\left(1 + \\frac{1.0}{0.005}\\right) = 50 \\times (1 + 200) = 50 \\times 201 = 10050 \\text{ µM}$$\n\nLet $[\\text{Tyr}]_{\\text{inh}}$ and $v_{\\text{HPD,inh}}$ be the plasma tyrosine concentration and HPD flux at the new steady state, respectively. The system is described by two coupled equations:\n1.  The HPD flux equation with inhibition:\n    $$v_{\\text{HPD,inh}} = \\frac{V_{\\max}\\,(\\alpha\\,[\\text{Tyr}]_{\\text{inh}})}{K_{m,\\text{app}} + (\\alpha\\,[\\text{Tyr}]_{\\text{inh}})}$$\n2.  The tyrosine mass balance equation, where $R_{\\text{in}}$ is assumed to be unchanged:\n    $$R_{\\text{in}} = k_{\\text{other}}\\,[\\text{Tyr}]_{\\text{inh}} + v_{\\text{HPD,inh}}$$\n\nWe can solve this system for the two unknowns, $[\\text{Tyr}]_{\\text{inh}}$ and $v_{\\text{HPD,inh}}$. Substitute the expression for $v_{\\text{HPD,inh}}$ from the balance equation ($v_{\\text{HPD,inh}} = R_{\\text{in}} - k_{\\text{other}}\\,[\\text{Tyr}]_{\\text{inh}}$) into the kinetic equation:\n$$R_{\\text{in}} - k_{\\text{other}}\\,[\\text{Tyr}]_{\\text{inh}} = \\frac{V_{\\max}\\,(\\alpha\\,[\\text{Tyr}]_{\\text{inh}})}{K_{m,\\text{app}} + (\\alpha\\,[\\text{Tyr}]_{\\text{inh}})}$$\n\nTo simplify, let $x = [\\text{Tyr}]_{\\text{inh}}$.\n$$(R_{\\text{in}} - k_{\\text{other}}\\,x)(K_{m,\\text{app}} + \\alpha x) = V_{\\max} \\alpha x$$\nExpanding this gives a quadratic equation in the form $Ax^2 + Bx + C = 0$:\n$$R_{\\text{in}} K_{m,\\text{app}} + R_{\\text{in}} \\alpha x - k_{\\text{other}} K_{m,\\text{app}} x - k_{\\text{other}} \\alpha x^2 = V_{\\max} \\alpha x$$\n$$(k_{\\text{other}} \\alpha) x^2 + (k_{\\text{other}} K_{m,\\text{app}} + V_{\\max} \\alpha - R_{\\text{in}} \\alpha) x - R_{\\text{in}} K_{m,\\text{app}} = 0$$\n\nNow, we substitute the known values for the coefficients $A$, $B$, and $C$:\n$A = k_{\\text{other}} \\alpha = (0.01)(0.2) = 0.002$\n$B = (0.01)(10050) + (\\frac{217}{6})(0.2) - (7.6)(0.2) = 100.5 + \\frac{217}{30} - 1.52 \\approx 100.5 + 7.2333 - 1.52 = 106.2133...$\n$C = -(7.6)(10050) = -76380$\n\nThe quadratic equation is:\n$$0.002 x^2 + 106.2133... x - 76380 = 0$$\nWe solve for $x$ using the quadratic formula, $x = \\frac{-B \\pm \\sqrt{B^2 - 4AC}}{2A}$. Since $x$ represents a concentration, it must be a positive value.\n$$x = \\frac{-106.2133... \\pm \\sqrt{(106.2133...)^2 - 4(0.002)(-76380)}}{2(0.002)}$$\n$$x = \\frac{-106.2133... \\pm \\sqrt{11281.271... - (-611.04)}}{0.004}$$\n$$x = \\frac{-106.2133... \\pm \\sqrt{11892.311...}}{0.004}$$\n$$x = \\frac{-106.2133... \\pm 109.05187...}{0.004}$$\nChoosing the positive root:\n$$x = \\frac{-106.2133... + 109.05187...}{0.004} = \\frac{2.83854...}{0.004} \\approx 709.635 \\text{ µM}$$\nSo, the post-treatment plasma tyrosine concentration is $[\\text{Tyr}]_{\\text{inh}} \\approx 709.635$ µM.\n\nNow, we calculate the post-treatment HGA production rate, $v_{\\text{HPD,inh}}$, using the mass balance equation:\n$$v_{\\text{HPD,inh}} = R_{\\text{in}} - k_{\\text{other}}\\,[\\text{Tyr}]_{\\text{inh}}$$\n$$v_{\\text{HPD,inh}} = 7.6 - (0.01) \\times (709.635)$$\n$$v_{\\text{HPD,inh}} = 7.6 - 7.09635 = 0.50365 \\text{ mmol/day}$$\n\nFinally, we round each value to four significant figures as requested.\n- Daily HGA production rate: $v_{\\text{HPD,inh}} \\approx 0.5036$ mmol/day.\n- Plasma tyrosine concentration: $[\\text{Tyr}]_{\\text{inh}} \\approx 709.6$ µM.\n\nThe final answer is a row matrix of these two values.", "answer": "$$\n\\boxed{\\begin{pmatrix} 0.5036 & 709.6 \\end{pmatrix}}\n$$", "id": "5010601"}]}